Inventor · disambiguated record
Robert W. Payne
Also filed as: PAYNE ROBERT · PAYNE ROBERT W · PAYNE ROBERT WALTER
36 granted patents·7 pending applications·655 citations·filing 2013–2025
99Inventor score
Top patents by PatentIndex Score
43 records- 0198US10716852B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Jul 21, 2020·10 cites·22 claims
- 0298US10155039B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted Dec 18, 2018·21 cites·12 claims
- 0398US9861695B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Jan 9, 2018·31 cites·25 claims
- 0498US9808525B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2015·Granted Nov 7, 2017·24 cites·11 claims
- 0598US9789185B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Oct 17, 2017·23 cites·27 claims
- 0698US9782480B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Oct 10, 2017·25 cites·10 claims
- 0798US9782479B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2015·Granted Oct 10, 2017·23 cites·20 claims
- 0898US9770507B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Sep 26, 2017·25 cites·8 claims
- 0998US9757454B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Sep 12, 2017·23 cites·29 claims
- 1098US9737600B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Aug 22, 2017·25 cites·9 claims
- 1198US9731008B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Aug 15, 2017·26 cites·20 claims
- 1298US9731009B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Aug 15, 2017·25 cites·8 claims
- 1398US9724415B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Aug 8, 2017·25 cites·10 claims
- 1498US9724414B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2015·Granted Aug 8, 2017·23 cites·25 claims
- 1598US9707293B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Jul 18, 2017·25 cites·15 claims
- 1698US9682145B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2016·Granted Jun 20, 2017·23 cites·29 claims
- 1798US9382317B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2015·Granted Jul 5, 2016·55 cites·10 claims
- 1898US9346880B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2015·Granted May 24, 2016·44 cites·20 claims
- 1998US9340611B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2015·Granted May 17, 2016·43 cites·12 claims
- 2098US9340612B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2015·Granted May 17, 2016·42 cites·20 claims
- 2197US10207000B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted Feb 19, 2019·16 cites·11 claims
- 2297US10195275B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Feb 5, 2019·15 cites·25 claims
- 2397US10159733B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted Dec 25, 2018·15 cites·9 claims
- 2497US10159732B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted Dec 25, 2018·15 cites·13 claims
- 2596US10722579B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Jul 28, 2020·5 cites·22 claims
- 2696US10716853B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Jul 21, 2020·5 cites·22 claims
- 2796US10716854B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Jul 21, 2020·5 cites·22 claims
- 2894US10799585B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Oct 13, 2020·2 cites·16 claims
- 2994US10772960B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Sep 15, 2020·2 cites·16 claims
- 3094US10772959B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Sep 15, 2020·2 cites·16 claims
- 3194US10688183B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2018·Granted Jun 23, 2020·2 cites·16 claims
- 3293US10786566B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted Sep 29, 2020·2 cites·17 claims
- 3393US10780163B2Stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted Sep 22, 2020·2 cites·29 claims
- 3491US10286071B2Syringe containing stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted May 14, 2019·3 cites·20 claims
- 3591US10286072B2Methods of manufacturing stable aqueous formulations of adalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Granted May 14, 2019·3 cites·20 claims
- 3673US2018028655A1Stable Aqueous Formulations of AdalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 3773US2018028656A1Stable Aqueous Formulations of AdalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 3873US2018028657A1Stable Aqueous Formulations of AdalimumabCOHERUS BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 3971US12427185B2Formulations of MANP and uses thereofE STAR BIOTECH LLC·Filed 2024·Granted Sep 30, 2025·0 cites·39 claims
- 4071US2014186361A1Stable Aqueous Formulations of AdalimumabCOHERUS BIOSCIENCES INC·Filed 2013·Application pending·0 cites
- 4154US2024309104A1Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4253US2025186553A1Formulations of MANP and Uses ThereofE STAR BIOTECH LLC·Filed 2025·Application pending·0 cites
- 4344US2021322549A1Stable Aqueous Formulations of NatalizumabCOHERUS BIOSCIENCES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert W. Payne files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →